Phenotypic Clusters Predict Outcomes in a Longitudinal Interstitial Lung Disease Cohort

Chest

Volumn 153, Issue 2, 2018, Pages 349-360

  Adegunsoye, Ayodeji ^a   Oldham, Justin M ^b   Chung, Jonathan H ^a   Montner, Steven M ^a   Lee, Cathryn ^a   Witt, Leah J ^a   Stahlbaum, Danielle ^a   Bermea, Rene S ^a   Chen, Lena W ^a   Hsu, Scully ^a   Husain, Aliya N ^a   Noth, Imre ^a   Vij, Rekha ^a   Strek, Mary E ^a   Churpek, Matthew ^a  

^a UNIVERSITY OF CHICAGO   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

cluster; interstitial lung disease; mortality; phenotype; pulmonary fibrosis

Indexed keywords

ANTIGEN; ANTINUCLEAR ANTIBODY; CARBON MONOXIDE; PARAPROTEIN;

ADULT; AFRICAN AMERICAN; AGED; ALLERGIC PNEUMONITIS; ANTIBODY TITER; ARTICLE; CAUCASIAN; CHRONIC DISEASE; CLINICAL OUTCOME; CLUSTER ANALYSIS; COHORT ANALYSIS; CONNECTIVE TISSUE DISEASE ASSOCIATED INTERSTITIAL LUNG DISEASE; DISEASE CLASSIFICATION; DISEASE FREE SURVIVAL; EMPHYSEMA; ENVIRONMENTAL EXPOSURE; FEMALE; FIBROSING ALVEOLITIS; FORCED VITAL CAPACITY; HIGH RESOLUTION COMPUTER TOMOGRAPHY; HONEYCOMBING; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INTERSTITIAL LUNG DISEASE; INTERSTITIAL PNEUMONIA WITH AUTOIMMUNE FEATURE; LONGITUDINAL STUDY; LUNG DIFFUSION CAPACITY; MAJOR CLINICAL STUDY; MALE; OBESITY; PHENOTYPE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RADIOLOGICAL PARAMETERS; SMOKING; TRANSPLANT FREE SURVIVAL; YOUNG ADULT; CLASSIFICATION; LUNG FIBROSIS; MIDDLE AGED; PATHOLOGY;

AGED; CHRONIC DISEASE; CLUSTER ANALYSIS; FEMALE; HUMANS; LONGITUDINAL STUDIES; LUNG DISEASES, INTERSTITIAL; MALE; MIDDLE AGED; PHENOTYPE; PULMONARY FIBROSIS;

EID: 85041910988     PISSN: 00123692     EISSN: 19313543     Source Type: Journal    
DOI: 10.1016/j.chest.2017.09.026     Document Type: Article

References (36)

1. Antoniou, K.M., Margaritopoulos, G.A., Tomassetti, S., Bonella, F., Costabel, U., Poletti, V., Interstitial lung disease. Eur Respir Rev 23:131 (2014), 40–54.
2. Travis, W.D., Costabel, U., Hansell, D.M., et al. An official American Thoracic Society/European Respiratory Society statement: update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med 188:6 (2013), 733–748.
3. Yagihashi, K., Huckleberry, J., Colby, T.V., et al. Radiologic-pathologic discordance in biopsy-proven usual interstitial pneumonia. Eur Respir J 47:4 (2016), 1189–1197.
4. Hutchinson, J.P., Fogarty, A.W., McKeever, T.M., Hubbard, R.B., In-hospital mortality after surgical lung biopsy for interstitial lung disease in the United States. 2000 to 2011. Am J Respir Crit Care Med 193:10 (2016), 1161–1167.
5. Corte, T.J., Copley, S.J., Desai, S.R., et al. Significance of connective tissue disease features in idiopathic interstitial pneumonia. Eur Respir J 39:3 (2012), 661–668.
6. Kinder, B.W., Collard, H.R., Koth, L., et al. Idiopathic nonspecific interstitial pneumonia: lung manifestation of undifferentiated connective tissue disease?. Am J Respir Crit Care Med 176:7 (2007), 691–697.
7. Vij, R., Noth, I., Strek, M.E., Autoimmune-featured interstitial lung disease: a distinct entity. Chest 140:5 (2011), 1292–1299.
8. Omote, N., Taniguchi, H., Kondoh, Y., et al. Lung-dominant connective tissue disease: clinical, radiologic, and histologic features. Chest 148:6 (2015), 1438–1446.
9. Fischer, A., Antoniou, K.M., Brown, K.K., et al. An official European Respiratory Society/American Thoracic Society research statement: interstitial pneumonia with autoimmune features. Eur Respir J 46:4 (2015), 976–987.
10. Ryerson, C.J., Vittinghoff, E., Ley, B., et al. Predicting survival across chronic interstitial lung disease: the ILD-GAP model. Chest 145:4 (2014), 723–728.
11. Lee, S.H., Kim, S.Y., Kim, D.S., et al. Predicting survival of patients with idiopathic pulmonary fibrosis using GAP score: a nationwide cohort study. Respir Res, 17(1), 2016, 131.
12. Khanna, D., Mittoo, S., Aggarwal, R., et al. Connective tissue disease-associated interstitial lung diseases (CTD-ILD)—report from OMERACT CTD-ILD Working Group. J Rheumatol 42:11 (2015), 2168–2171.
13. Tomassetti, S., Ryu, J.H., Poletti, V., Staging systems and disease severity assessment in interstitial lung diseases. Curr Opin Pulm Med 21:5 (2015), 463–469.
14. Rennard, S.I., Locantore, N., Delafont, B., et al. Identification of five chronic obstructive pulmonary disease subgroups with different prognoses in the ECLIPSE cohort using cluster analysis. Ann Am Thoracic Soc 12:3 (2015), 303–312.
15. Moore, W.C., Meyers, D.A., Wenzel, S.E., et al. Identification of asthma phenotypes using cluster analysis in the Severe Asthma Research Program. Am J Respir Crit Care Med 181:4 (2010), 315–323.
16. Martínez-García, M.A., Vendrell, M., Girón, R., et al. The multiple faces of non-cystic fibrosis bronchiectasis: a cluster analysis approach. Ann Am Thorac Soc 13:9 (2016), 1468–1475.
17. American Thoracic Society, European Respiratory Society. American Thoracic Society/European Respiratory Society international multidisciplinary consensus classification of the idiopathic interstitial pneumonias. This joint statement of the American Thoracic Society (ATS), and the European Respiratory Society (ERS) was adopted by the ATS board of directors, June 2001 and by the ERS Executive Committee, June 2001. Am J Respir Crit Care Med 165:2 (2002), 277–304.
18. Raghu, G., Collard, H.R., Egan, J.J., et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 183:6 (2011), 788–824.
19. Raghu, G., Rochwerg, B., Zhang, Y., et al. An official ATS/ERS/JRS/ALAT clinical practice guideline: treatment of idiopathic pulmonary fibrosis. An update of the 2011 clinical practice guideline. Am J Respir Crit Care Med 192:2 (2015), e3–e19.
20. Chung, J.H., Montner, S.M., Adegunsoye, A., et al. CT Findings, radiologic-pathologic correlation, and imaging predictors of survival for patients with interstitial pneumonia with autoimmune features. AJR Am J Roentgenol 208:6 (2017), 1229–1236.
21. King, T.E. Jr., Bradford, W.Z., Castro-Bernardini, S., et al. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med 370:22 (2014), 2083–2092.
22. La, D., Livesay, D.R., Predicting functional sites with an automated algorithm suitable for heterogeneous datasets. BMC Bioinformatics, 6, 2005, 116.
23. Kaufman L, Rousseeuw PJ. Finding Groups in Data: An Introduction to Cluster Analysis. New York, NY: Wiley; 2009.
24. Gower, J.C., A general coefficient of similarity and some of its properties. Biometrics 27:4 (1971), 857–874.
25. Rousseeuw, P.J., Silhouettes—a graphical aid to the interpretation and validation of cluster-analysis. J Computational Appl Mathematics 20 (1987), 53–65.
26. Raghu, G., Wells, A.U., Nicholson, A.G., et al. Effect of nintedanib in subgroups of idiopathic pulmonary fibrosis by diagnostic criteria. Am J Respir Crit Care Med 195:1 (2017), 78–85.
27. Singh, S., Collins, B.F., Sharma, B.B., et al. Interstitial lung disease (ILD) in India: results of a prospective registry. Am J Respir Crit Care Med 195:6 (2017), 801–813.
28. Morell, F., Villar, A., Montero, M.A., et al. Chronic hypersensitivity pneumonitis in patients diagnosed with idiopathic pulmonary fibrosis: a prospective case-cohort study. Lancet Respir Med 1:9 (2013), 685–694.
29. Ryerson, C.J., Urbania, T.H., Richeldi, L., et al. Prevalence and prognosis of unclassifiable interstitial lung disease. Eur Respir J 42:3 (2013), 750–757.
30. Ryerson CJ, Corte TJ, Lee JS, et al. A standardized diagnostic ontology for fibrotic interstitial lung disease: an international working group perspective [published online ahead of print April 17, 2017]. Am J Respir Crit Care Med. https://doi.org/10.1164/rccm.201702-0400PP.
31. Seibold, M.A., Wise, A.L., Speer, M.C., et al. A common MUC5B promoter polymorphism and pulmonary fibrosis. N Engl J Med 364:16 (2011), 1503–1512.
32. Peljto, A.L., Zhang, Y., Fingerlin, T.E., et al. Association between the MUC5B promoter polymorphism and survival in patients with idiopathic pulmonary fibrosis. JAMA 309:21 (2013), 2232–2239.
33. Oldham, J.M., Ma, S.F., Martinez, F.J., et al. TOLLIP, MUC5B, and the response to N-acetylcysteine among individuals with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 192:12 (2015), 1475–1482.
34. Podolanczuk, A.J., Raghu, G., Tsai, M.Y., et al. Cholesterol, lipoproteins and subclinical interstitial lung disease: the MESA study. Thorax 72:5 (2017), 472–474.
35. Vij, R., Noth, I., Peripheral blood biomarkers in idiopathic pulmonary fibrosis. Transl Res 159:4 (2012), 218–227.
36. Raghu, G., Brown, K.K., Collard, H.R., et al. Efficacy of simtuzumab versus placebo in patients with idiopathic pulmonary fibrosis: a randomised, double-blind, controlled, phase 2 trial. Lancet Respir Med 5:1 (2017), 22–32.